Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00261313 | ACCELERATE: Doxorubicin and Cyclophosphamide Followed by Paclitaxel With Pegfilgrastim and Darbepoetin Alfa Support for the Treatment of Women With Breast Cancer | PHASE2 | COMPLETED | 80 | — | — | Dec 1, 2005 | Dec 1, 2007 | Feb 26, 2010 | - | — |
| Arm | Type | Description |
|---|---|---|
| Aranesp | EXPERIMENTAL | - |
| Neulasta | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| Neulasta | DRUG | 6mg Neulasta to be given approximately 24 hours afer each cycle of chemotherapy |
| Aranesp | DRUG | If Hb drops below 110, 300mcg Aranesp will be administered. |
Inclusion Criteria: * Breast cancer diagnosis node-positive or high risk node negative * Estrogen receptor (ER) negative or ER positive (stage IIA, IIB or IIIA) disease. Exclusion Criteria: * Metastatic breast cancer * Clinically significant cardiac disease